Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belapectin for prevention of esophageal varices in compensated NASH cirrhosis
MOH_2020-09-21_009339Phase 3Active, not recruiting
- Sponsor
- Galectin Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of belapectin in Cirrhosis and Portal Hypertension (PH) (3 arms), sponsored by Galectin Therapeutics. Started Sep 2020; status: active, not recruiting.
02
Drugs
belapectin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on MOH_2020-09-21_009339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-21_009339.